Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and unresectable advanced, metastatic, or recurrent solid tumors lacking appropriate approved treatment options, including NSCLC and other squamous cancers, receive intravenous IDP-001. This investigational bispecific antibody–drug conjugate targets EGFR and CDCP1 and delivers the microtubule-disrupting payload monomethyl auristatin E.

ClinicalTrials.gov ID: NCT07602842

A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic hepatocellular carcinoma, or advanced uveal melanoma, renal cell, non-small-cell lung, or colorectal cancer after standard therapy or when standard therapy is inappropriate, receive oral VMD-102 monotherapy. VMD-102 is an investigational selective inhibitor of protein kinase C epsilon (PKCε/PRKCE).

ClinicalTrials.gov ID: NCT07636785

A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with advanced solid tumors after standard therapy has failed or is unsuitable receive intravenous BNT317, an investigational bispecific antibody targeting PD-1 and CD39, in dose escalation. Expansion cohorts evaluate BNT317 alone in previously treated clear-cell renal cell carcinoma and with standard-of-care chemotherapy in previously treated HER2-negative gastric or gastroesophageal-junction cancer and non-small-cell lung cancer without actionable alterations.

ClinicalTrials.gov ID: NCT06750185

A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of STX-003 Delivered Intravenously in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors and no curative option after standard therapy receive intravenous STX-003 alone or with pembrolizumab; expansion cohorts focus on previously treated PD-L1-positive NSCLC and cutaneous melanoma. STX-003 is a lipid nanoparticle–delivered, self-replicating mRNA therapy designed to drive tumor-selective IL-12 expression and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT07751042

A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of AQUA07 Monotherapy and Combination Therapy in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic ALK-positive NSCLC that has progressed after prior systemic therapy, including at least one ALK inhibitor other than crizotinib alone, receive oral AQUA07 alone or with lorlatinib. AQUA07 is an investigational allosteric ALK inhibitor that binds outside the ATP-binding pocket; lorlatinib is an ATP-competitive ALK/ROS1 inhibitor.

ClinicalTrials.gov ID: NCT07617337

A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic EGFR-mutant NSCLC that has progressed on a third-generation EGFR inhibitor receive oral H002, an investigational fourth-generation EGFR tyrosine kinase inhibitor designed to target activating EGFR mutations and resistance mutations including C797S. The expansion cohort requires centrally confirmed EGFR C797S.

ClinicalTrials.gov ID: NCT05519293

FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or recurrent solid tumors after standard therapy receive intravenous AG01, an investigational antibody targeting progranulin/GP88 to inhibit tumor growth and survival signaling. Expansion cohorts enroll previously treated patients with triple-negative or hormone-resistant breast cancer, non-small-cell lung cancer, or mesothelioma, generally requiring tumor GP88 expression.

ClinicalTrials.gov ID: NCT05627960

A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated advanced or metastatic solid tumors, ECOG 0–1, measurable disease, and a biopsiable tumor receive intravenous or subcutaneous ST-067, alone, after obinutuzumab pretreatment, or with pembrolizumab. ST-067 is an engineered IL-18 that activates the IL-18 receptor while resisting neutralization by IL-18 binding protein; expansion cohorts focus on melanoma, renal cell, triple-negative breast, non-small cell lung, head and neck squamous cell, and MSI-high cancers.

ClinicalTrials.gov ID: NCT04787042

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced selected solid tumors who have exhausted or are ineligible for standard treatment receive oral TT-10 (PORT-6), an adenosine A2A receptor antagonist, oral TT-4 (PORT-7), an adenosine A2B receptor antagonist, or both. Eligible tumor types vary by cohort and include RCC, CRPC, NSCLC, head and neck, colorectal, endometrial, and ovarian cancers.

ClinicalTrials.gov ID: NCT04969315

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, recurrent or metastatic HER2-positive solid tumors and ECOG performance status 0–1 receive XMT-2056 monotherapy, a HER2-targeted antibody–drug conjugate that delivers a STING agonist to stimulate innate immune signaling. Untreated or progressive CNS metastases and prior STING-directed therapy are excluded.

ClinicalTrials.gov ID: NCT05514717